Antibiotic Resistant Infections
항생제 내성 감염

Antibiotic Resistant Infections(항생제 내성 감염)란 무엇입니까?

Antibiotic Resistant Infections 항생제 내성 감염 - BACKGROUND Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli) are responsible for the increase of antibiotic-resistant infections across the globe. ^[1] The formation of biofilms by clinical pathogens typically leads to chronic and recurring antibiotic-resistant infections. ^[2] Background Antibiotic-resistant infections have become a public health crisis that is driven by the inappropriate use of antibiotics. ^[3] Treatment of antibiotic-resistant infections is dependent on the detection of specific bacterial genes or proteins in clinical assays. ^[4] The global spread of antibiotic-resistant infections has meant that there is an urgent need to develop new antimicrobial alternatives. ^[5] While the risk factors for antibiotic resistance are well known, there remains a large need for the early identification of antibiotic-resistant infections. ^[6] These cases also highlight the efficacy of phages in overcoming antibiotic-resistant infections as well as biofilm infections. ^[7] Antibiotic-resistant infections present a serious health concern worldwide. ^[8] Extensive misuse of antibacterial drugs unnecessarily will result in an alarming increase in antibiotic-resistant infections after the COVID-19 pandemic. ^[9] Finding better ways to predict, prevent, and treat antibiotic-resistant infections will have a major positive impact on the care of those with cancer. ^[10] Background and Aim: Now-a-days antibiotics are the main tool for correcting the pathological conditions of pigs; unfortunately, antibiotics are a potential threat to the environment, as they lead to the spread of antibiotic-resistant infections. ^[11] Therefore, different antibiotic therapies for various wards and distinct age groups (especially between pediatric and elderly patients) should be considered to control the emergence and spread of highly antibiotic-resistant infections. ^[12] In order to fill this gap in quantitative understanding of the development of antibiotic-resistant infections in wastewater, we have developed a mathematical model synthesizing many known drivers of antibiotic resistance in these settings to help predict the growth of resistant populations in different environmental scenarios. ^[13] Interpretation Analysing the gastrointestinal resistome can provide insights into the effects of antibiotics on the risk of antibiotic-resistant infections. ^[14] A total of 84 researchers from 17 fields of ID research participated in the survey (predominant research fields: gastrointestinal infections n=11, healthcare-associated and antibiotic-resistant infections n=10, hepatitis n=10). ^[15] 8 million antibiotic-resistant infections in the U. ^[16] CLINICAL SIGNIFICANCE In vitro TLR-3 activation of equine MSCs tested here may be a strategy to improve antibacterial properties of MSCs to treat antibiotic-resistant infections. ^[17] Development of alternative therapeutic options is urgently demanded for the patients who have antibiotic-resistant infections. ^[18] The Fenton process activated by Zero Valent Iron (ZVI-Fenton) is shown here to effectively remove antibiotics reserved for hospital settings (specifically used to treat antibiotic-resistant infections) from wastewater, thereby helping in the fight against bacterial resistance. ^[19] Pneumococcal vaccination reduces disease incidence, prevents antibiotic use, and decreases antibiotic-resistant infections. ^[20] Antibiotic-resistant infections present significant challenges to patients. ^[21] This work demonstrates the potential for the clinical use of this method to test for antibiotic-resistant infections. ^[22] Background and Aim: Antibiotic-resistant infections are one of the leading threats to public health globally. ^[23] Patients with solid cancer and ESBL-E infections require special management since they are a population with a high threat of antibiotic-resistant infections. ^[24] Additionally, antibiotic-resistant infections pose a serious public health concern; therefore, antibiotic-alternative approaches are needed to reduce transmission of C. ^[25] The reasons for the increasing prevalence of antibiotic-resistant infections are complex and associated with myriad clinical and environmental processes. ^[26] These findings can inform targeted stewardship interventions to reduce inappropriate antibiotic prescribing and to decrease the rates of antibiotic-resistant infections. ^[27] This threat is the deepest in the developing world, with an estimated 700,000 people suffering from antibiotic-resistant infections each year. ^[28] Phages are already utilized in the health care industry to treat antibiotic-resistant infections, such as those on implant-associated biofilms and in compassionate-care cases. ^[29] Pseudomonas aeruginosa is a frequent cause of antibiotic-resistant infections. ^[30] Some clinicians are turning to bacteriophage therapy for the treatment of antibiotic-resistant infections. ^[31] One relatively underreported intersection between health and climate change is that of infections, particularly antibiotic-resistant infections. ^[32] Bacteriophages infecting pathogenic hosts play an important role in medical research, not only as potential treatments for antibiotic-resistant infections but also offering novel insights into pathogen genetics and evolution. ^[33] The recent upsurge of antibiotic-resistant infections has posed to be a serious health concern worldwide. ^[34] Development of novel therapeutics to treat antibiotic-resistant infections, especially those caused by ESKAPE pathogens, is urgent. ^[35] Antibiotic-resistant infections are already widespread in the Sub-Saharan Africa and across the globe. ^[36] Antibiotic-resistant infections caused by extended-spectrum β-lactamases (ESBLs) and carbapenemases are increasing worldwide. ^[37] FT shows a strong potential for antibacterial therapy and could be used as a substance in the design of antibacterial drugs for pharmaceutical intervention including therapy of antibiotic-resistant infections. ^[38] To combat the ongoing public health threat of antibiotic-resistant infections, a technology that can quickly identify infecting bacterial pathogens and concurrently perform antimicrobial susceptibility testing (AST) in point-of-care settings is needed. ^[39] Lastly, we explore how these systems may be promising targets for the development of antivirulence therapeutics to combat antibiotic-resistant infections. ^[40] Antibiotic-resistant infections on the health care system and the population have put a burden on economic and adequate health. ^[41] Using antibiotics limits antibiotic-treatable infections, but fosters the growth of antibiotic-resistant infections. ^[42] This knowledge will aid in the future design of new drugs against antibiotic-resistant infections. ^[43] 8 million antibiotic-resistant infections in the United States of America per year. ^[44] Phage therapy is currently one of the most promising solutions to combat antibiotic-resistant infections. ^[45] In this work we investigated the feasibility of the electrochemical degradation in synthetic urine of cefazolin (CFZ), an antibiotic used for the treatment of antibiotic-resistant infections, which could be carried out in hospital wards on source-separated urine. ^[46] Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics for combating antibiotic-resistant infections. ^[47] Further, they showed that these peptides likely affect MlaA-OmpC/F, a system critical for maintaining bacterial outer membrane lipid asymmetry, which represents a high-value target for treating antibiotic-resistant infections. ^[48] Phage therapy is currently one of the most promising solutions to combat antibiotic-resistant infections. ^[49] It has been suggested that by 2050, antibiotic-resistant infections could cause ten million deaths each year. ^[50]
배경 그람 음성 ESKAPE 병원체(Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa 및 Escherichia coli)는 전 세계적으로 항생제 내성 감염의 증가에 책임이 있습니다. ^[1] 임상 병원체에 의한 생물막의 형성은 일반적으로 만성 및 재발성 항생제 내성 감염으로 이어집니다. ^[2] 배경 항생제 내성 감염은 항생제의 부적절한 사용으로 인한 공중 보건 위기가 되었습니다. ^[3] 항생제 내성 감염의 치료는 임상 분석에서 특정 박테리아 유전자 또는 단백질의 검출에 달려 있습니다. ^[4] 항생제 내성 감염의 세계적 확산은 새로운 항생제 대안 개발이 시급하다는 것을 의미합니다. ^[5] 항생제 내성의 위험인자는 잘 알려져 있지만 항생제 내성 감염의 조기 발견에 대한 필요성이 여전히 크다. ^[6] 이러한 사례는 또한 항생제 내성 감염 및 생물막 감염을 극복하는 파지의 효능을 강조합니다. ^[7] 항생제 내성 감염은 전 세계적으로 심각한 건�